Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer

Clin Cancer Res. 2017 Feb 1;23(3):618-622. doi: 10.1158/1078-0432.CCR-15-2815. Epub 2016 Nov 7.

Abstract

In 2015, the FDA approved an unprecedented number of new therapies for non-small cell lung cancer (NSCLC), among them therapies addressing specific genomic tumor subsets in the setting of development of resistance to first-line targeted therapy. Osimertinib (Tagrisso, formerly AZD9291; AstraZeneca) is indicated for patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor therapy. It received breakthrough therapy designation, priority review status, and accelerated approval from the FDA. Clin Cancer Res; 23(3); 618-22. ©2016 AACR.

Publication types

  • Review

MeSH terms

  • Acrylamides / therapeutic use
  • Adenosine Triphosphate / metabolism
  • Aniline Compounds
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Binding Sites / drug effects
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / enzymology
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Diarrhea / chemically induced
  • Disease Progression
  • Drug Eruptions / etiology
  • Drug Resistance, Neoplasm
  • ErbB Receptors / antagonists & inhibitors*
  • ErbB Receptors / genetics
  • Genes, erbB-1
  • Humans
  • Lung Diseases, Interstitial / chemically induced
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / enzymology
  • Lung Neoplasms / genetics
  • Molecular Targeted Therapy*
  • Mutation, Missense
  • Neoplasm Proteins / antagonists & inhibitors*
  • Neoplasm Proteins / genetics
  • Piperazines / adverse effects
  • Piperazines / pharmacology
  • Piperazines / therapeutic use*
  • Point Mutation
  • Protein Kinase Inhibitors / adverse effects
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrimidines / therapeutic use
  • Salvage Therapy
  • Single-Blind Method

Substances

  • Acrylamides
  • Aniline Compounds
  • Antineoplastic Agents
  • Neoplasm Proteins
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • osimertinib
  • rociletinib
  • Adenosine Triphosphate
  • EGFR protein, human
  • ErbB Receptors